Hepacure

Hepacure Overview

Hepacure Pharma is developing a novel peptide therapy targeting fatty liver diseases, particularly non-alcoholic fatty liver disease (NAFLD). NAFLD encompasses conditions marked by excess fat in the liver, increasing the risk of serious health issues like diabetes and kidney disease. Advanced NAFLD forms, such as non-alcoholic steatohepatitis (NASH), lead to inflammation, fibrosis, and, in some cases, incurable carcinoma. Hepacure’s therapy centers on a peptide called Luji, which targets fibrosis and reactivates immune responses in the liver. This peptide blocks key proteins in the fibrosis pathway and reactivates natural killer (NK) cells, enabling them to target hepatic stellate cells (HSCs), which contribute to fibrosis. Research highlights Neuroligin-4 (NLGN4X) as a factor in NK cell inhibition, leading to fibrosis progression. Luji modulates the NLGN4-Nrx1β protein interaction, aiming to prevent fibrosis advancement. In preclinical fibrosis mouse models, Luji demonstrated potential by slowing fibrosis progression and reducing liver inflammation and enzyme damage. It is designed for once-weekly injections to treat early-stage fibrosis (F2 stage), with the aim of preventing further liver deterioration in NAFLD patients.

Cumulative Funding Raised Over Time ($)

Latest News

No news articles.

Funding

Team Members

1

Employees: 1-10

Web & Social Links

Locations

Israel

Photos & Videos

No files yet

Hepacure Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info